> Orasis Pharmaceuticals closed a $13 million (€11 million) series B round. The Israeli biotech will use the money to take a treatment for presbyopia symptoms through a phase 2b trial. Statement
> Ali Mortazavi stepped down as CEO of Silence Therapeutics. Annalisa Jenkins, the former CEO of Dimension Therapeutics and current chair of Silence, will expand her role at the RNA specialist to cover for the loss of Mortazavi while a permanent replacement is sought. Release
> InflaRx opened a research facility in Ann Arbor, Michigan. The German biotech set up the facility to further its work on complement system-based therapeutics. Statement
> The FDA cleared Cellectis to trial its third off-the-shelf CAR-T therapy, UCART22, in patients with B-cell acute lymphoblastic leukemia. Release
> Nanobiotix sought to reassure investors as its stock spiralled downward. Management at the French biotech said “no news or particular event, that would not have been disclosed to the public, has happened.” Statement